Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric J Small

Showing results (211-220 of 361) with videos related to

Pageof 37
Sort By:
Clinical Genitourinary Cancer|October 18, 2018
Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 StudyMina Lee, Haemin Hong, Won Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2018
Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall SurvivalEmmanuel S Antonarakis, Eric J Small, Daniel P Petrylak, et al.
The Oncologist|August 11, 2019
Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trialDaniel J George, Colin Hessel, Susan Halabi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2017
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN TrialToni K Choueiri, Susan Halabi, Ben L Sanford, et al.
Urologic Oncology|February 6, 2017
A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium studyRahul Aggarwal, Alan Bryce, Charles J Ryan, et al.
Journal of Vascular and Interventional Radiology : JVIR|May 28, 2017
CT-Guided Bone Biopsies in Metastatic Castration-Resistant Prostate Cancer: Factors Predictive of Maximum Tumor YieldMichael G Holmes, Erik Foss, Gabby Joseph, et al.
Oncotarget|October 27, 2017
Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancerJennifer Podolak, Kristi Eilers, Timothy Newby, et al.
European Urology|December 17, 2021
Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTANFred Saad, Eric J Small, Felix Y Feng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2009
Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916Maha Hussain, Bryan Goldman, Cathy Tangen, et al.
Urologic Oncology|August 16, 2022
Hypoxia-inducible factor pathway genes predict survival in metastatic clear cell renal cell carcinomaPatrick K Tamukong, Paige Kuhlmann, Sungyong You, et al.
Pageof 37

Showing results (211-220 of 361) with videos related to

Sort By:
Pageof 37
Clinical Genitourinary Cancer|October 18, 2018
Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 StudyMina Lee, Haemin Hong, Won Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2018
Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall SurvivalEmmanuel S Antonarakis, Eric J Small, Daniel P Petrylak, et al.
The Oncologist|August 11, 2019
Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trialDaniel J George, Colin Hessel, Susan Halabi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2017
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN TrialToni K Choueiri, Susan Halabi, Ben L Sanford, et al.
Urologic Oncology|February 6, 2017
A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium studyRahul Aggarwal, Alan Bryce, Charles J Ryan, et al.
Journal of Vascular and Interventional Radiology : JVIR|May 28, 2017
CT-Guided Bone Biopsies in Metastatic Castration-Resistant Prostate Cancer: Factors Predictive of Maximum Tumor YieldMichael G Holmes, Erik Foss, Gabby Joseph, et al.
Oncotarget|October 27, 2017
Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancerJennifer Podolak, Kristi Eilers, Timothy Newby, et al.
European Urology|December 17, 2021
Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTANFred Saad, Eric J Small, Felix Y Feng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2009
Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916Maha Hussain, Bryan Goldman, Cathy Tangen, et al.
Urologic Oncology|August 16, 2022
Hypoxia-inducible factor pathway genes predict survival in metastatic clear cell renal cell carcinomaPatrick K Tamukong, Paige Kuhlmann, Sungyong You, et al.
Pageof 37